Deficiency of plasma ADAMTS13 activity, either hereditary or acquired, causes thrombotic thrombocytopenic purpura (TTP). However, the triggering events and mechanisms underlying the pathogenesis of TTP are not fully understood. Emerging data suggest that complement activation may be associated with both hemolytic uremic syndrome (HUS) and TTP.
In Aim 1, we propose to determine the effects of CFH on ADAMTS13- mediated VWF proteolysis and its adhesive function under flow. We will also determine the kinetics and mechanism of such interactions and how such an interaction affects complement activation/inactivation.
In Aim 2, we will determine the role of genetic or acquired deficiency of CFH on the occurrence, progression, and outcome of acquired TTP (with inhibitors) in murine models.
In Aim 3, we propose to determine the prevalence of mutations in genes in complement components and regulators in patients with acquired TTP patients with inhibitors. We pursue the hypothesis that by inhibiting complement activation with anti-complement therapy either alone or in combination with rADAMTS13 one can better prevent the onset and progression of the disease pathology or accelerate its recovery. The results of the proposed study will advance our understanding of the fundamental role of CFH in regulation of VWF function under physiological shear stress, shed new light on the mechanisms of acquired TTP, and provide invaluable tools for testing the efficacy of novel therapeutics.
This project aims to understand the pathogenesis of thrombotic thrombocytopenic purpura (TTP) by determining the interactions between complement factor H (CFH) and von Willebrand factor and metalloprotease ADAMTS13. We propose to test the hypothesis that genetic or antibody-mediated inactivation of CFH and ADAMTS13 may have a cooperative role in pathogenesis of TTP. The results of the proposed study will shed new lights on the crosstalk between complement and hemostasis, and provide invaluable murine models for further testing novel therapeutic strategies of potentially fatal thrombotic microangiopathy including TTP and hemolytic uremic syndrome.
Showing the most recent 10 out of 21 publications
